<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567590</url>
  </required_header>
  <id_info>
    <org_study_id>KY 2018-027-02</org_study_id>
    <nct_id>NCT03567590</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Sphenopalatine Ganglion Pulsed Radiofrequency Treatment for Cluster Headache</brief_title>
  <official_title>A Prospective, Multicentre, Randomized, Controlled, Blinded-endpoint Study to Evaluate the Efficacy and Safety of Sphenopalatine Ganglion Pulsed Radiofrequency Treatment for Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Sanbo Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Province People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the effectiveness and safety of sphenopalatine ganglion
      pulsed radiofrequency on cluster headache.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to investigate whether the sphenopalatine ganglion pulsed
      radiofrequency treatment is better than traditional sphenopalatine ganglion nerve block
      technology and provides medical evidence for the clinical application and promotion of
      sphenopalatine ganglion pulsed radiofrequency treatment to provide a minimally invasive,
      safe, and effective treatment for patients with cluster headache who do not respond to drug
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">April 24, 2021</completion_date>
  <primary_completion_date type="Actual">April 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of the cluster period</measure>
    <time_frame>Within 1 year (the cluster period is not over 3 months generally)</time_frame>
    <description>The duration of the cluster period is defined as the total duration of the headache, including the pain attack time before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The degree of pain during headache attacks after treatment</measure>
    <time_frame>1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery</time_frame>
    <description>Evaluated by numeric rating scale (NRS, 0 points for no pain and 10 points for the most severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache attack frequency</measure>
    <time_frame>1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery</time_frame>
    <description>The number of attacks per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of each headache attack</measure>
    <time_frame>1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery</time_frame>
    <description>Duration of each headache attack after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of auxiliary analgesic drugs</measure>
    <time_frame>1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery</time_frame>
    <description>Dose of auxiliary analgesic drugs per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission period</measure>
    <time_frame>1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery</time_frame>
    <description>From the end of this cluster period to the beginning of the next cluster period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery</time_frame>
    <description>Patient satisfactory scale (PSS) evaluation (0 for unsatisfactory, and 10 for very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective rate</measure>
    <time_frame>1 day, 3 days, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 1 year after surgery</time_frame>
    <description>The effectiveness rate is calculated as follows: effectiveness rate = the number of effective patients / total number of patients in this group × 100%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Pulsed Radiofrequency Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will undergo pulsed radiofrequency treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerve Block Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will undergo nerve block treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulsed Radiofrequency treatment</intervention_name>
    <description>The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.</description>
    <arm_group_label>Pulsed Radiofrequency Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nerve Block treatment</intervention_name>
    <description>A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.</description>
    <arm_group_label>Nerve Block Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of cluster headache is confirmed according to the diagnostic criteria of the
             2018 International Classification of Headache Disorders 3rd edition (ICHD-3);

          -  patient's age is between 18 and 60 years;

          -  patients seek treatment in the pain clinics of hospitals participating in the study
             within 5 days of the onset of the cluster period; pain conditions of patients remain
             the same after conservative treatment of conventional oral medication, or the
             reduction rates are less than 50% in pain degree during headache attacks, headache
             attack frequency, duration of each headache attack, and auxiliary analgesic drug
             dosage; and

          -  patients signed the informed consent.

        Exclusion Criteria:

          -  abnormalities in blood measurements, liver and kidney function, blood glucose,
             coagulation, electrocardiogram, and chest radiograph;

          -  infection at the puncture site;

          -  previous mental illness;

          -  previous history of narcotic drug abuse;

          -  history of anticoagulant and antiplatelet aggregation drugs;

          -  implantable pulse generator;

          -  previous history of invasive treatments such as sphenopalatine ganglion radiofrequency
             thermocoagulation and chemical destruction;

          -  pregnant or breastfeeding patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang Luo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Sanbo Brain Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100093</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Province People's Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Weaver-Agostoni J. Cluster headache. Am Fam Physician. 2013 Jul 15;88(2):122-8. Review.</citation>
    <PMID>23939643</PMID>
  </reference>
  <reference>
    <citation>Peñarrocha-Diago M, Boronat A, Peñarrocha-Oltra D, Ata-Ali J, Bagan JV, Peñarrocha-Diago M. Clinical course of patients with episodic cluster headache treated with corticosteroids inproximity to the sphenopalatine ganglion: a preliminary study of 23 patients. Med Oral Patol Oral Cir Bucal. 2012 May 1;17(3):e477-82.</citation>
    <PMID>22143727</PMID>
  </reference>
  <reference>
    <citation>Lepper A, Frese A, Summ O, Nofer JR, Evers S. Hypothalamic dopaminergic stimulation in cluster headache. Cephalalgia. 2013 Oct;33(14):1155-9. doi: 10.1177/0333102413487445. Epub 2013 Apr 29.</citation>
    <PMID>23630400</PMID>
  </reference>
  <reference>
    <citation>Loomba V, Upadhyay A, Kaveeshvar H. Radiofrequency Ablation of the Sphenopalatine Ganglion Using Cone Beam Computed Tomography for Intractable Cluster Headache. Pain Physician. 2016 Sep-Oct;19(7):E1093-6.</citation>
    <PMID>27676681</PMID>
  </reference>
  <reference>
    <citation>Kohlmeier C, Behrens P, Böger A, Ramachandran B, Caparso A, Schulze D, Stude P, Heiland M, Assaf AT. Improved surgical procedure using intraoperative navigation for the implantation of the SPG microstimulator in patients with chronic cluster headache. Int J Comput Assist Radiol Surg. 2017 Dec;12(12):2119-2128. doi: 10.1007/s11548-016-1512-2. Epub 2017 Jan 12.</citation>
    <PMID>28083804</PMID>
  </reference>
  <reference>
    <citation>Barloese MC, Jürgens TP, May A, Lainez JM, Schoenen J, Gaul C, Goodman AM, Caparso A, Jensen RH. Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. J Headache Pain. 2016 Dec;17(1):67. doi: 10.1186/s10194-016-0658-1. Epub 2016 Jul 26.</citation>
    <PMID>27461394</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Fang Luo</investigator_full_name>
    <investigator_title>Director of Department of Pain Management</investigator_title>
  </responsible_party>
  <keyword>Cluster Headache, pulsed radiofrequency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

